Physician profile
Edgar Kahn
NPI 1225181217
$806.65
in general payments reported to CMS, 2019-2025
16 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.24 · 2022: $79.07 · 2023: $170 · 2024: $285 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $142.89 | 2023-2025 | |
| Exact Sciences Corporation | $115.51 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $105.56 | 2023-2024 | Spravato |
| Vanda Pharmaceuticals INC. | $58.79 | 2024 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $54.54 | 2022-2025 | Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $54.30 | 2023-2025 | Cobenfy, Camzyos |
| Neurocrine Biosciences, INC. | $50.39 | 2024-2025 | Ingrezza |
| Novo Nordisk INC | $47.03 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.96 | 2021 | |
| Idorsia Pharmaceuticals US INC | $35.19 | 2022-2023 | Quviviq |
| Daiichi Sankyo INC. | $21.20 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.80 | 2025 | Caplyta |
| Antares Pharma, INC. | $16.69 | 2025 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $15.65 | 2021 | |
| Alkermes, INC. | $15.08 | 2023 | Vivitrol |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.